{
    "xml": "<topic id=\"PHP1417\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/dopexamine-hydrochloride\" basename=\"dopexamine-hydrochloride\" title=\"DOPEXAMINE HYDROCHLORIDE\">\n<title>DOPEXAMINE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_704\" namespace=\"/interactions/list-of-drug-interactions/sympathomimetics/dopexamine\">Dopexamine</xref>\n</p>\n<data name=\"vtmid\">349922000</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_822593647\" title=\"Sympathomimetics (inotropic)\">Sympathomimetics (inotropic)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP48535\" outputclass=\"drugAction\" rev=\"1.10\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dopexamine acts on beta<sub>2</sub> receptors in cardiac muscle to produce a positive inotropic effect; and on peripheral dopamine receptors to increase renal perfusion; it is reported not to induce vasoconstriction.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48488\" outputclass=\"indicationsAndDose\" rev=\"1.25\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Inotropic support and vasodilator in exacerbations of chronic heart failure and in heart failure associated with cardiac surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8239;microgram/kg/minute, to be administered into central or large peripheral vein, then increased if necessary to 1&#8239;microgram/kg/minute, increased if necessary up to 6&#8239;micrograms/kg/minute, in increments of 0.5&#8211;1 microgram/kg/minute at intervals of not less than 15 minutes.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48567\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Aortic stenosis</ph>; <ph outputclass=\"contraindication\">hypertrophic cardiomyopathy</ph>; <ph outputclass=\"contraindication\">left ventricular outlet obstruction</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>; <ph outputclass=\"contraindication\">thrombocytopenia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48612\" outputclass=\"cautions\" rev=\"1.17\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Correct hypovolaemia before starting and during treatment</ph>; <ph outputclass=\"caution\">hyperglycaemia</ph>; <ph outputclass=\"caution\">hyperthyroidism</ph>; <ph outputclass=\"caution\">hypokalaemia</ph>; <ph outputclass=\"caution\">myocardial infarction</ph>; <ph outputclass=\"caution\">recent angina</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48483\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (sympathomimetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48442\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angina</ph>; <ph outputclass=\"sideEffect\">arrhythmias</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">myocardial infarction</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">reversible thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48480\" outputclass=\"pregnancy\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No information available&#8212;manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48384\" outputclass=\"monitoringRequirements\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor blood pressure, pulse, plasma potassium, and blood glucose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48417\" outputclass=\"treatmentCessation\" rev=\"1.9\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Avoid abrupt withdrawal.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48668\" outputclass=\"directionsForAdministration\" rev=\"1.16\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Concentrate for intravenous infusion to be diluted before use.</p>\n<p>For <i>continuous intravenous infusion</i>, dilute to a concentration of 400 or 800&#8239;micrograms/mL with Glucose 5% <i>or </i>Sodium Chloride 0.9%; max. concentration <i>via</i> large peripheral vein 1&#8239;mg/mL, concentrations up to 4&#8239;mg/mL may be infused <i>via</i> central vein; give <i>via</i> infusion pump or other device which provides accurate control of rate; contact with metal in infusion apparatus should be minimised; incompatible with bicarbonate.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1417-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/dopexamine-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74667\" title=\"Solution for infusion\" namespace=\"/drugs/dopexamine-hydrochloride/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_704\" namespace=\"/interactions/list-of-drug-interactions/sympathomimetics/dopexamine\" title=\"Dopexamine\" count=\"1\" rel=\"link\">Dopexamine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74667\" namespace=\"/drugs/dopexamine-hydrochloride/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP1417",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/dopexamine-hydrochloride",
    "basename": "dopexamine-hydrochloride",
    "title": "DOPEXAMINE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_704",
            "label": "Dopexamine"
        }
    ],
    "vtmid": "349922000",
    "drugClassification": [
        "Sympathomimetics (inotropic)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Dopexamine acts on beta2 receptors in cardiac muscle to produce a positive inotropic effect; and on peripheral dopamine receptors to increase renal perfusion; it is reported not to induce vasoconstriction.",
                "html": "<p>Dopexamine acts on beta<sub>2</sub> receptors in cardiac muscle to produce a positive inotropic effect; and on peripheral dopamine receptors to increase renal perfusion; it is reported not to induce vasoconstriction.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Inotropic support and vasodilator in exacerbations of chronic heart failure and in heart failure associated with cardiac surgery",
                        "html": "Inotropic support and vasodilator in exacerbations of chronic heart failure and in heart failure associated with cardiac surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "0.5 microgram/kg/minute, to be administered into central or large peripheral vein, then increased if necessary to 1 microgram/kg/minute, increased if necessary up to 6 micrograms/kg/minute, in increments of 0.5&#8211;1 microgram/kg/minute at intervals of not less than 15 minutes.",
                        "html": "<p>0.5&#8239;microgram/kg/minute, to be administered into central or large peripheral vein, then increased if necessary to 1&#8239;microgram/kg/minute, increased if necessary up to 6&#8239;micrograms/kg/minute, in increments of 0.5&#8211;1 microgram/kg/minute at intervals of not less than 15 minutes.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Aortic stenosis",
                "html": "Aortic stenosis"
            },
            {
                "type": "contraindications",
                "textContent": "hypertrophic cardiomyopathy",
                "html": "hypertrophic cardiomyopathy"
            },
            {
                "type": "contraindications",
                "textContent": "left ventricular outlet obstruction",
                "html": "left ventricular outlet obstruction"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            },
            {
                "type": "contraindications",
                "textContent": "thrombocytopenia",
                "html": "thrombocytopenia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Correct hypovolaemia before starting and during treatment",
                "html": "Correct hypovolaemia before starting and during treatment"
            },
            {
                "type": "cautions",
                "textContent": "hyperglycaemia",
                "html": "hyperglycaemia"
            },
            {
                "type": "cautions",
                "textContent": "hyperthyroidism",
                "html": "hyperthyroidism"
            },
            {
                "type": "cautions",
                "textContent": "hypokalaemia",
                "html": "hypokalaemia"
            },
            {
                "type": "cautions",
                "textContent": "myocardial infarction",
                "html": "myocardial infarction"
            },
            {
                "type": "cautions",
                "textContent": "recent angina",
                "html": "recent angina"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (sympathomimetics).",
                "html": "<p>Appendix 1 (sympathomimetics).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Angina",
                        "html": "Angina",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arrhythmias",
                        "html": "arrhythmias",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myocardial infarction",
                        "html": "myocardial infarction",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "reversible thrombocytopenia",
                        "html": "reversible thrombocytopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No information available&#8212;manufacturer advises avoid.",
                "html": "<p>No information available&#8212;manufacturer advises avoid.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor blood pressure, pulse, plasma potassium, and blood glucose.",
                "html": "<p>Monitor blood pressure, pulse, plasma potassium, and blood glucose.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Avoid abrupt withdrawal.",
                "html": "<p>Avoid abrupt withdrawal.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Concentrate for intravenous infusion to be diluted before use.\n\nFor continuous intravenous infusion, dilute to a concentration of 400 or 800 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%; max. concentration via large peripheral vein 1 mg/mL, concentrations up to 4 mg/mL may be infused via central vein; give via infusion pump or other device which provides accurate control of rate; contact with metal in infusion apparatus should be minimised; incompatible with bicarbonate.",
                "html": "<p>Concentrate for intravenous infusion to be diluted before use.</p><p>For <i>continuous intravenous infusion</i>, dilute to a concentration of 400 or 800&#8239;micrograms/mL with Glucose 5% <i>or </i>Sodium Chloride 0.9%; max. concentration <i>via</i> large peripheral vein 1&#8239;mg/mL, concentrations up to 4&#8239;mg/mL may be infused <i>via</i> central vein; give <i>via</i> infusion pump or other device which provides accurate control of rate; contact with metal in infusion apparatus should be minimised; incompatible with bicarbonate.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74667",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_704",
                "label": "Dopexamine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74667",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}